Conjugate Or Complex Includes Virus Or Componenet Thereof Patents (Class 424/196.11)
-
Publication number: 20140205628Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.Type: ApplicationFiled: December 16, 2013Publication date: July 24, 2014Applicant: WORLD FORCE TECHNOLOGIES, LLCInventors: Thomas W. Konowalchuk, Jack Konowalchuk
-
Publication number: 20140205629Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: March 28, 2014Publication date: July 24, 2014Applicant: AlphaVax, Inc.Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
-
Patent number: 8784825Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.Type: GrantFiled: August 28, 2009Date of Patent: July 22, 2014Assignee: Taiga Biotechnologies, Inc.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Patent number: 8765666Abstract: The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked.Type: GrantFiled: April 9, 2010Date of Patent: July 1, 2014Assignee: Instytut Bio chemii i Biofizki PANInventors: Ewa Szolajska, Jadwiga Chroboczek, Monika Zochowska
-
Publication number: 20140170172Abstract: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: PIN Pharma, Inc.Inventor: David I. Cohen
-
Publication number: 20140141037Abstract: Complexes that contain RSV F ectodomain polypeptides and methods for making the complexes are disclosed. The RSV F ectodomain polypeptides can be in the prefusion form.Type: ApplicationFiled: November 19, 2013Publication date: May 22, 2014Applicant: Novartis AGInventors: Kurt Swanson, Andrea Carfi
-
Publication number: 20140141036Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.Type: ApplicationFiled: December 20, 2012Publication date: May 22, 2014Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin F. Bachmann, Franziska Lechner, Taizo Storni
-
Patent number: 8715685Abstract: This invention discloses a group of 298 peptides from which several peptides are independently selected and synthesized in their stereoisomer and chemically modified forms, and conjugated to a polymer via linkers creating novel anti-HIV-1 multi-peptide-polymer conjugate compounds for the treatment and prevention of HIV-1 infection. The peptides mimic the domains of major HIV-1 proteins, and therefore, they function as inhibitors of the targeted HIV-1 proteins. The polymer is a useful delivery system for the stereoisomer peptides, and certain peptides are peptide-ligands for targeted delivery into the HIV infected cells.Type: GrantFiled: July 14, 2010Date of Patent: May 6, 2014Inventor: Lucia Irene Gonzalez
-
Publication number: 20140120131Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicant: Novavax ABInventors: Bror Morein, Karin Lövgren Bengtsson
-
Publication number: 20140112950Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.Type: ApplicationFiled: March 2, 2012Publication date: April 24, 2014Inventors: Manmohan Singh, Barbara Baudner, David Skibinski
-
Publication number: 20140105992Abstract: The present provide vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed on to a particle of metal salt and the resulting particle is essentially devoid of antigen.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Nathalie GARCON
-
Publication number: 20140086869Abstract: Compositions and methods for diagnosing and treating tumors using myeloid derived suppressor cells (MDSCs) are provided. More particularly, the compositions contain labeled MDSCs or MDSCs in combination with oncolytic viruses, nano-particles or other anti-tumor agents.Type: ApplicationFiled: October 20, 2011Publication date: March 27, 2014Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventor: Shu-Hsia Chen
-
Publication number: 20140079730Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: NOVARTIS AGInventors: Ana GRAF, Matthias STAUFENBIEL, Thomas BLÄTTLER, Paolo PAGANETTI
-
Patent number: 8663651Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.Type: GrantFiled: December 23, 2007Date of Patent: March 4, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
-
Patent number: 8658179Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.Type: GrantFiled: October 17, 2012Date of Patent: February 25, 2014Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
-
Patent number: 8658180Abstract: Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.Type: GrantFiled: August 14, 2009Date of Patent: February 25, 2014Inventors: Mark A. Miller, Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Zuzana Biesova, Jerry Keith
-
Patent number: 8637044Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.Type: GrantFiled: March 22, 2012Date of Patent: January 28, 2014Assignee: Novartis AGInventors: Susan Barnett, Rino Rappuoli, Victoria A Sharma, Indresh K Srivastava, Jan Zur Megede
-
Patent number: 8628784Abstract: An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle.Type: GrantFiled: February 28, 2008Date of Patent: January 14, 2014Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Nathalie Garcon
-
Patent number: 8617566Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: May 13, 2013Date of Patent: December 31, 2013Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
-
Publication number: 20130337005Abstract: Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.Type: ApplicationFiled: April 22, 2013Publication date: December 19, 2013Applicant: Midatech LimitedInventor: Midatech Limited
-
Publication number: 20130315966Abstract: The disclosure provides a method of preparing an immunologically-active adjuvant-bound freeze dried vaccine composition. A specific embodiment provides a stable vaccine composition comprising an aluminum-salt adjuvant, a recombinant Clostridium botulinum neurotoxin protein and a glass-forming agent. These vaccine compositions are useful in the treatment of humans and other animals at risk of infection from Clostridium botulinum neurotoxin.Type: ApplicationFiled: May 20, 2013Publication date: November 28, 2013Applicant: The Regents of the University of ColoradoInventors: Theodore Randolph, Amber Clausi, John F. Carpenter, Daniel K. Schwartz
-
Publication number: 20130315949Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: December 7, 2012Publication date: November 28, 2013Applicant: Cytos Biotechnology AGInventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Publication number: 20130302366Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.Type: ApplicationFiled: May 8, 2013Publication date: November 14, 2013Inventor: Christopher Marshall
-
Publication number: 20130295043Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: February 29, 2012Publication date: November 7, 2013Applicant: CUREVAC GMBHInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Publication number: 20130295131Abstract: We have generated virus-like particles (VLPs) that can display other proteins through covalent protein-protein linkages mediated by the ‘Dock and Lock’ interaction between the Drosophila NorpA protein and the C-terminal pentapeptide tail of the InaD protein. This interaction may also be mediated by a portion of the SITAC protein and the Tetraspanin L6 Antigen protein. This system can be used to generate high-density scaffolded arrays of epitopes for immunization. This technology can streamline VLP vaccine candidate production, making it possible to rapidly evaluate panels of candidates in response to current vaccine needs and emerging pathogen threats.Type: ApplicationFiled: November 5, 2010Publication date: November 7, 2013Inventor: Hal S. Padgett
-
Publication number: 20130259879Abstract: The present invention is directed to an inventive composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such an inventive composition or vaccine composition and to the second medical use of such an inventive composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein. The present invention furthermore discloses kits comprising such a composition or vaccine composition.Type: ApplicationFiled: February 10, 2012Publication date: October 3, 2013Applicant: CUREVAC GMBHInventors: Patrick Baumhof, Karl-Josef Kallen, Mariola Fotin-Mleczek
-
Publication number: 20130251744Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.Type: ApplicationFiled: February 15, 2013Publication date: September 26, 2013Applicant: VLP THERAPEUTICS, LLCInventors: Ryuji UENO, Wataru AKAHATA
-
Patent number: 8541002Abstract: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.Type: GrantFiled: September 13, 2004Date of Patent: September 24, 2013Assignee: Agenus Inc.Inventors: Alemseged Truneh, Daniel L. Levey, Xiaoyan Mo, Kenneth P. Leclair, Ramesh S. Kashi, Chuanliang Liu
-
Publication number: 20130236491Abstract: A novel type of particle platform for application in biotechnology is provided by the present invention. Said platforms comprise RNA-free particles generated by thermal denaturation and structural remodeling of helical plant viruses. Tobamovir-uses and, in particular, tobacco mosaic virus (TMV) coat protein (CP) subunits, denatured, at high temperatures are specifically self-assembled by two-stage assembly into the spherical particles (SPs) of similar shape and varying size including nanoparticles (SNPs) with a diameter up to 100-150 nm and spherical microparticles (SMPs) with a diameter up to 800 nm and more. The size of said SPs depends on the virus concentration used and, therefore can be controlled. Said SPs are biologically safe, highly stable and highly immunogenic. Said SNPs and SMPs are structurally distinct from viruses presently known. They are unique, having no protein nano-particle analogs in the nature.Type: ApplicationFiled: February 15, 2011Publication date: September 12, 2013Inventors: Iosif Grigorievich Atabekov, Olga Viacheslavovna Karpova, Mikhail Petrovich Kirpichnikov, Nikolay Alexandrovich Nikitin, Sergey Nikolaevich Chirkov, Ekaterina Alexeevna Trifonova, Anna Alexandrovna Sheveleva, Marina Vladimirovna Archipenko
-
Publication number: 20130224144Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: ApplicationFiled: September 18, 2012Publication date: August 29, 2013Applicant: Etubics CorporationInventors: Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
-
Publication number: 20130224235Abstract: A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein and DNA vaccines, based on potato virus A coat protein.Type: ApplicationFiled: October 19, 2009Publication date: August 29, 2013Applicants: University of Tartu, Tallinn University of TechnologyInventors: Lilian Järvekülg, Viiu Paalme, Ülo Puurand, Sirje Rüütel Boudinot, Sulev Kuuse, Reet Rumvolt, Ave Laas
-
Patent number: 8512712Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.Type: GrantFiled: February 29, 2012Date of Patent: August 20, 2013Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Publication number: 20130183355Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.Type: ApplicationFiled: June 7, 2011Publication date: July 18, 2013Applicant: NOVARTIS AGInventors: Siddhartha Jain, Derek O'Hagan, Manmohan Singh
-
Publication number: 20130171186Abstract: GB1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds. Also provided are hemagglutinin mimics and fragments and methods of using the same, including methods of screening for GB1 peptidic compounds and methods of using conjugates the mimics as influenza A vaccines. Aspects of the invention include methods of screening libraries of L-peptidic compounds for specific binding to a D-peptidic hemagglutinin target protein. Once a L-peptidic compound has been identified that specifically binds to the D-peptidic hemagglutinin target protein, the D-enantiomer of the selected L-peptidic compound may be produced. In some embodiments, the D-enantiomer of the selected L-peptidic compound binds to, and in some instances, neutralizes influenza virus particles.Type: ApplicationFiled: November 30, 2012Publication date: July 4, 2013Applicants: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, REFLEXION PHARMACEUTICALSInventors: Reflexion Pharmaceuticals, The Governing Council of the University of Toronto
-
Publication number: 20130171234Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.Type: ApplicationFiled: February 25, 2011Publication date: July 4, 2013Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
-
Patent number: 8460676Abstract: The present invention relates to uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: December 17, 2010Date of Patent: June 11, 2013Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
-
Publication number: 20130142821Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: ApplicationFiled: May 21, 2012Publication date: June 6, 2013Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Patrik Maurer
-
Publication number: 20130101617Abstract: Embodiments of the present invention are drawn to pure forms of human or simian immunodeficiency virus trimeric gp120/gp41 Env protein (Env trimers) and methods for making them. These embodiments address the need for an authentic immunogen lacking uncleaved gp160 Env protein and/or other forms of Env, such as gp41 “stumps” dissociated from gp120, which interfere with neutralizing antibody production in a vaccinated subject.Type: ApplicationFiled: June 29, 2011Publication date: April 25, 2013Applicant: TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventor: James Binley
-
Publication number: 20130095133Abstract: The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.Type: ApplicationFiled: March 29, 2011Publication date: April 18, 2013Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique - CNRS, Universidad Catolica de Cordoba (UCC), Assistance Publique Hopitaux de Paris, Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Universite Pierre et Marie Curie (Paris 6)Inventors: David Klatzmann, Eliane Piaggio, Hugo Daniel Luján
-
Publication number: 20130084306Abstract: Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.Type: ApplicationFiled: May 27, 2011Publication date: April 4, 2013Applicant: Coley Pharmaceutical Group Inc.Inventors: Heather Lynn Davis, Risini Weeratna, Paul J. Dominowski
-
Patent number: 8404247Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: June 23, 2011Date of Patent: March 26, 2013Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Patent number: 8388979Abstract: Delivery proteins are provided for transferring a protein, antibody or foreign substance into a cell without impairing the function or structure thereof. Further, methods of transferring a foreign substance into a cell at a high efficiency by using the delivery protein or an envelope virus or inactivated envelope virus in combination with said delivery protein are provided. The inventors discovered that a protein containing a polypeptide having an affinity for a constituent of the envelope virus contributes to the efficient enclosure of the foreign substance in the envelope. Moreover, the inventors discovered that use of the delivery protein enables foreign substances to be included in an envelope virus or inactivated envelope virus and therefore makes it possible to efficiently transfer the substances into cells without damaging the physiological function thereof.Type: GrantFiled: July 11, 2012Date of Patent: March 5, 2013Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Kuni Fushikida, Yoshitaka Kondo
-
Patent number: 8383129Abstract: The present invention refers to the use of rotavirus proteins VP4, VP8 and their derived fusion proteins and peptides, for enhancing the delivery of pharmaceutical agents through the paracellular pathway. These rotavirus proteins and derived peptides may additionally be employed to reduce unwanted cellular adhesion that can occur between cancerous cells, or between normal cells as a result of surgery, injury, chemotherapy, disease, inflammation or other pathological conditions.Type: GrantFiled: January 10, 2003Date of Patent: February 26, 2013Assignee: Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico NacionalInventors: Lorenza Gonzalez-Mariscal, Porfirio Nava-Dominguez
-
Publication number: 20130028930Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.Type: ApplicationFiled: April 8, 2011Publication date: January 31, 2013Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
-
Patent number: 8357496Abstract: Method for the diagnosis or the screening of an arbovirus infection and preferably a flaviviridae infection and more preferably a flavivirus infection, reagents useful in said method and their applications. Said method comprises: (i) contacting a sample from the subject or animal with a solid support sensitized with an Ig binding protein which is directed against a specific class of Ig molecules of the subject or animal species under consideration and (ii) incubating the immunocomplex formed in (i) with a detector molecule consisting of a hybrid protein comprising at least an arboviral ED3 domain and an alkaline phosphatase (PhoA), the detection of said immunocomplex being the sign of the presence of an arbovirus in said sample.Type: GrantFiled: June 13, 2008Date of Patent: January 22, 2013Assignees: Institut Pasteur, Centre National de La Recherche ScientifiqueInventors: Hugues Bedouelle, Elodie Brient-Litzler, Philippe Dussart, Philippe Despres, Laetitia Bremand
-
Publication number: 20130011432Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.Type: ApplicationFiled: March 17, 2011Publication date: January 10, 2013Applicant: CORNELL UNIVERSITY (CCTEC)Inventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky
-
Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant
Publication number: 20130011431Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. In one embodiment, the construct containing the A?1-6 peptide consists of a virus-like particle (VLP) of the RNA bacteriophage Q? chemically coupled to said A?1-6 peptide.Type: ApplicationFiled: March 28, 2011Publication date: January 10, 2013Applicant: NOVARTIS AGInventors: Peter Ulrich, Katja Baer, Georges Imbert, Marie-Jose Hoellinger, Marie-Emmanuelle Riviere, Ana Graf -
Publication number: 20130004534Abstract: Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Inventor: Adan Rios
-
Publication number: 20120321699Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Inventors: Barton F. Haynes, Hua-Xin Liao, Georgia Tomaras, Thomas B. Kepler, Kwan-Ki Hwang, S.Munir Alam, Yang Liu, T. Matt Holl, Guang Yang, Garnett Kelsoe, Mattia Bonsignori
-
Publication number: 20120321659Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: ApplicationFiled: April 26, 2012Publication date: December 20, 2012Applicant: BIOGEN IDEC MA INC.Inventor: Kenneth Murray